Vaccination News
Breaking News Archives - each day's breaking news from December 1, 2003 (check here for breaking news you might have missed and breaking news that didn't ever hit the "front page")
More News - all the news most recently posted on this website
All the News - a running tab of everything posted on this website since October 29, 2003
Top Stories Archives - daily breaking and other important news stories
Daily News Archives - all the news posted on this website each day (from April 2001)
Hot Topics - selected stories, by category
Return to Vaccination News Home Page (for best results, right click to "open in new window")
Subscribe to the Vaccination NewsLetter
View past & current Scandals (columns by Sandy Mintz)
Search This Site using keywords
click here to download Adobe Reader click here for Picks of the Week click here for the old "Recommended List"
Note that "Excreted vaccine-derived viruses often
are more virulent
than the original OPV strains". SM
****
Date: Mon, 29 Jan 2001 19:03:46 -0500 (EST)
From: ProMED-mail <promed@promed.isid.harvard.edu>
Subject: PRO> Polio, circulation of vaccine-derived virus
POLIO, CIRCULATION OF VACCINE-DERIVED VIRUS
<http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5003a3.htm>
Circulation of Vaccine-derived Poliovirus Type 2 in Egypt, 1982-1993
--------------------------------------------------------------------
The finding that vaccine-derived polioviruses may circulate under suitable conditions
presents an additional challenge to efforts to eradicate polio worldwide.
During the year 2000, circulation of type 1 vaccine-derived poliovirus in the
Dominican Republic and Haiti was associated with 19 suspected polio cases.
Nucleotide sequence relationships among Sabin 2-derived polioviruses isolated
in China during the mid-1990s also were
consistent with establishment of genetic lineages by person-to-person
transmission.
This MMWR report summarizes the results of a study indicating that oral poliovirus
vaccine (OPV)-derived poliovirus type 2 circulated in Egypt during the 1980s
and early 1990s and caused widespread infection and paralytic disease. The
findings underscore the need for countries using OPV to target communities with
low vaccine coverage for intense vaccination activities to prevent circulation
of both wild and vaccine-derived
polioviruses.
During 1988-1993, 32 polio cases associated with vaccine-derived poliovirus
type 2 were found in 8 of 27 Governorates in Egypt. Although initial antigenic
characterization of the isolates indicated that they had non-vaccine-like
properties, nucleotide sequence analysis (i.e., comparing the 903 nucleotides
encoding the major capsid protein, VP1) performed during 1999 revealed that all
of the isolates were related (93%--96% nucleotide sequence identity) to the
Sabin type 2 OPV strain (Sabin 2). The isolates were not related (less than 81%
nucleotide sequence identity) to the wild type 2 poliovirus that had been
indigenous to Egypt (last isolated in 1979) or to any other wild type 2
polioviruses. The isolates also differed from type 2 vaccine-derived
polioviruses normally isolated from patients with
acute flaccid paralysis that typically are related closely (>99.5%
nucleotide sequence identity) to Sabin 2.
Both epidemiologic and genetic data among the 32 case isolates indicate
extensive circulation of type 2 vaccine-derived polioviruses in Egypt during
1988--1993. Several type 2 isolates were associated with clusters of cases
within the same Governorate, and sustained circulation of Sabin 2-derived
poliovirus probably occurred in some communities. The isolates grouped into
approximately 10 genetic lineages (corresponding to chains of transmission),
and isolates from the same Governorate usually were closely related. The extent
of VP1 sequence divergence from Sabin 2 was similar for isolates for any given
year, and divergence increased at a nearly constant rate from 1988 to 1993.
However, the sequence diversity (4%--5%) of the early isolates
suggested that circulation had started several years before 1988.
Although the precise duration and extent of vaccine-derived poliovirus
circulation in Egypt is uncertain because of gaps in surveillance before 1990,
regression analysis of the VP1 evolution rate suggested that all lineages
derived from one OPV infection that occurred approximately during 1982, and
that progeny from that initiating infection circulated in Egypt during
1982--1993. The time estimate of the initiating OPV infection is based on the
assumption that the rate of VP1 evolution was nearly constant
throughout the period of virus circulation.
Circulation of the Sabin 2-derived poliovirus occurred when OPV coverage
probably was low in the affected communities. OPV coverage rates increased
steadily in the mid-1990s, and no highly divergent vaccine-derived poliovirus
isolates have been found in Egypt since 1993. Low OPV coverage following the
elimination of at least one indigenous wild poliovirus serotype probably is
critical for circulation of vaccine-derived
polioviruses. Such conditions permit expansion of the cohort of children who
are not immune to one or more poliovirus serotypes. The threshold rates of
vaccine coverage needed to suppress circulation of vaccine-derived polioviruses
are unknown but probably vary by poliovirus serotype and environmental factors
(e.g., population density, levels of sanitation, and climate). However, when
OPV coverage rates are sufficient to prevent
circulation of wild polioviruses, they probably are sufficient to prevent
circulation of vaccine-derived polioviruses
Because the outbreak described in this report involved extensive
person-to-person transmission of poliovirus, it differs from vaccine-associated
paralytic polio (VAPP). Cases of VAPP are not linked epidemiologically or
virologically to each other, but are associated with separate recent exposures
to OPV. However, the early events associated with the circulation of
vaccine-derived polioviruses may be similar to events associated with contact
cases of VAPP: an unimmunized person is exposed to vaccine-derived poliovirus
excreted by a recent OPV recipient. Excreted vaccine-derived viruses often are
more virulent than the original OPV strains. Low levels of population immunity
may favor the selection and transmission of vaccine-derived variants with
biologic properties
indistinguishable from those of wild polioviruses.
The outbreak in the [the island of Hispaniola] involved circulating poliovirus
type 1; the cases in China and Egypt (and possibly infections detected by
environmental surveillance in Israel [9]) involved circulating type 2
vaccine-derived viruses. The type 2 OPV strain is the most transmissible of the
3 poliovirus serotypes. Because circulation of wild type 2 polioviruses
probably has ceased worldwide, the only type 2 polioviruses infecting humans
and conferring type-specific immunity are likely to be those derived from OPV.
The potential of vaccine-derived polioviruses to establish and maintain
circulation has important implications for developing an appropriate strategy
for the cessation of vaccination with OPV after wild poliovirus eradication has
been achieved. Potential vaccine-derived poliovirus circulation also
underscores the importance of maintaining high rates of poliovirus vaccine
coverage worldwide. Countries using OPV should target
communities with low vaccine coverage for intensified vaccination activities to
prevent circulation of vaccine-derived and wild polioviruses. Countries using
inactivated poliovirus vaccine [IPV] should take steps to ensure high coverage
rates in all communities to prevent the transmission of imported polioviruses.
--
ProMED-mail
<promed@promedmail.org>
[This report provides an authoritative assessment of the epidemiological
relevance of the circulation of vaccine-derived virus in separate incidents
during the course of the global poliovirus eradication campaign. The
original report is supplemented by references.
Dr. Pedro Mas Lago has pointed out an error in his comment in the
ProMED-mail post entitled "Poliomyelitis - Dominican Republic &
Haiti." At
the end of the first paragraph the phrase "poliovirus type 1 related in
Israel", should read "poliovirus type 2 related in Israel". -
Mod.CP]
..........................................cp/pg/jw
*##########################################################*
ProMED-mail makes every effort to verify the reports that
are posted, but the accuracy and completeness of the
information, and of any statements or opinions based
thereon, are not guaranteed. The reader assumes all risks in
using information posted or archived by ProMED-mail. ISID
and its associated service providers shall not be held
responsible for errors or omissions or held liable for any
damages incurred as a result of use or reliance upon posted
or archived material.
************************************************************
Breaking News Archives - each day's breaking news from December 1, 2003 (check here for breaking news you might have missed and breaking news that didn't ever hit the "front page")
More News - all the news most recently posted on this website
All the News - a running tab of everything posted on this website since October 29, 2003
Top Stories Archives - daily breaking and other important news stories
Daily News Archives - all the news posted on this website each day (from April 2001)
Hot Topics - selected stories, by category
Return to Vaccination News Home Page (for best results, right click to "open in new window")
DISCLAIMER: All information, data, and material contained, presented, or provided here is for general information purposes only and is not to be construed as reflecting the knowledge or opinions of the publisher, and is not to be construed or intended as providing medical or legal advice. The decision whether or not to vaccinate is an important and complex issue and should be made by you, and you alone, in consultation with your health care provider.